Results 1 to 10 of about 20,468 (186)

Nocturnal penile erections: A retrospective study of the role of RigiScan in predicting the response to sildenafil in erectile dysfunction patients

open access: yesJournal of Advanced Research, 2018
Sildenafil enhances the nitric oxide–cGMP pathway of erection, which is claimed to have a role in nocturnal penile tumescence and rigidity (NPTR). This study aimed to find whether RigiScan can predict the response to sildenafil among erectile dysfunction
Samir M. Elhanbly   +3 more
doaj   +1 more source

The effect of sesame intake on adult albino rat testis during sildenafil long-term administration

open access: yesJournal of Basic and Applied Zoology, 2021
Background Sildenafil (Viagra) is widely used for the treatment of erectile dysfunction under various etiologies. Unfortunately, chronic administration of sildenafil negatively affects fertility.
M. Goweder Fawzia   +2 more
doaj   +1 more source

A Retrospective Study of Sildenafil Administration in 55 Cats with Cardiopulmonary Disease (2009–2021)

open access: yesAnimals
Sildenafil is a drug used to successfully manage a variety of cardiopulmonary disorders in people and dogs, but there is limited information on its use in cats.
Jasmine Huynh   +5 more
doaj   +1 more source

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor

open access: yesInfectious Disease Reports, 2015
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello   +7 more
doaj   +1 more source

The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings

open access: yesPharmaceutics
Sildenafil is used to treat pulmonary hypertension in neonatal intensive care unit (NICU) settings. As multiple intravenous (IV) medications are co-administered in NICU settings, we sought to investigate the physicochemical compatibility of sildenafil ...
D. Thisuri N. De Silva   +5 more
doaj   +1 more source

Resposta pressórica de pacientes com miocardiopatia chagásica ante o uso do sildenafil Pressure response in chagasic cardiomyopathy patients after using sildenafil

open access: yesArquivos Brasileiros de Cardiologia, 2007
OBJETIVO: Verificar o efeito do sildenafil na pressão arterial (PA) e freqüência cardíaca (FC) de indivíduos portadores de miocardiopata chagásica (MCC) e de disfunção ventricular sistólica grave ...
Rodrigo Abensur Athanazio   +4 more
doaj   +1 more source

The effect of sildenafil on maternal mortality and fetal adverse outcomes among pregnant patients with congenital heart disease-associated pulmonary artery hypertension: A retrospective cohort study

open access: yesAnnals of Pediatric Cardiology
Background and Aim: Maternal and fetal mortality in patients with congenital heart disease-associated pulmonary artery hypertension (CHD-PAH) is reported to be quite high. Sildenafil is the standard of care in PAH.
Nabila Sabri Nahdi   +4 more
doaj   +1 more source

Impact of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats.

open access: yesPLoS ONE, 2015
BackgroundMitochondrial large-conductance Ca2+-sensitive potassium (mBKCa) channels are involved in myocardial ischemic preconditioning. Their role in sildenafil-induced cardioprotection is unknown.
Friederike Behmenburg   +6 more
doaj   +1 more source

Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals

open access: yesBMC Research Notes, 2009
Background Sildenafil is a cyclic guanosine monophosphate-specific phosphodiesterase-5 inhibitor used for treating pulmonary hypertension. Although the use of sildenafil in patients under 18 years old is off-label, this inhibitor has been widely ...
Cabral Lucio M   +2 more
doaj   +1 more source

Sildenafil promotes osteogenic differentiation of human mesenchymal stem cells and inhibits bone loss by affecting the TGF-β signaling pathway

open access: yesStem Cell Research & Therapy
Background Osteoporosis, a common bone disorder, is primarily managed pharmacologically. However, existing medications are associated with non-trivial side-effects.
Menglong Hu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy